Hostname: page-component-8448b6f56d-tj2md Total loading time: 0 Render date: 2024-04-24T20:25:33.083Z Has data issue: false hasContentIssue false
  • English
  • Français

Assessment of Adverse Events Associated With Antiretroviral Regimens for Postexposure Prophylaxis for Occupational and Nonoccupational Exposures to Prevent Transmission of Human Immunodeficiency Virus

Published online by Cambridge University Press:  02 January 2015

A. Luque ,
S. Hulse ,
D. Wang ,
U. Shahzad ,
E. Tanzman ,
S. Antenozzi  and
B. Smith
A. Luque*
Affiliation:
Infectious Diseases Division, Department of Medicine, Rochester, New York
S. Hulse
Affiliation:
Infectious Diseases Division, Department of Medicine, Rochester, New York
D. Wang
Affiliation:
Department of Biostatistics and Computational Biology, Rochester, New York
U. Shahzad
Affiliation:
Infectious Diseases Division, Department of Medicine, Rochester, New York Department of Infectious Diseases, Allegheny General Hospital, Pittsburgh, Pennsylvania
E. Tanzman
Affiliation:
University of Rochester School of Medicine and Dentistry, University of Rochester Health Service, Rochester, New York
S. Antenozzi
Affiliation:
University of Rochester School of Medicine and Dentistry, University of Rochester Health Service, Rochester, New York
B. Smith
Affiliation:
University of Rochester School of Medicine and Dentistry, University of Rochester Health Service, Rochester, New York
*
University of Rochester Medical Center, Box 689, 601 Elmwood Ave., Rochester, NY 14642 (amneris_luque@urmc.rochester.edu)
Get access Rights & Permissions [Opens in a new window]

Abstract

Objective.

To assess adverse events associated with antiretroviral regimens for human immunodeficiency virus (HIV) postexposure prophylaxis (PEP), with a particular focus on the treatment combination of zidovudine, lamivudine, and tenofovir (ZDV-3TC-TDF).

Methods.

Retrospective chart review for individuals who received HIV PEP for occupational and nonoccupational exposure, and multivariate analyses to identify risk factors for noncompletion of PEP and adverse events associated with PEP.

Setting.

University of Rochester Health Service Occupational Health Program and University of Rochester AIDS Center.

Participants.

Healthcare workers who received HIV PEP for occupational exposure from January 1, 1999, to December 31, 2004, and individuals who received HIV PEP for nonoccupational exposure from January 1, 2002, to December 31, 2004.

Results.

We found increased rates of nausea among subjects who received treatment with ZDV-3TC-TDF and subjects who received treatment with zidovudine, lamivudine, and indinavir (ZDV-3TC-IDV). Analyses showed that female sex was a risk factor for nausea. Compared with subjects who received treatment with ZDV-3TC-TDF, subjects who received treatment with ZDV-3TC-IDV were less likely to not complete the HIV PEP for occupational exposure.

Conclusion.

Preventive treatment of adverse events may be necessary to ensure completion of HIV PEP.

Type
Original Articles
Information
Infection Control & Hospital Epidemiology , Volume 28 , Issue 6 , June 2007 , pp. 695 - 701
Copyright
Copyright © The Society for Healthcare Epidemiology of America 2007

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

1.US Public Health Service. Updated U.S. Public Health Service guidelines for the management of occupational exposures to HBV, HCV, and HIV and recommendations for postexposure prophylaxis. MMWR Recomm Rep 2001;50(RR-11): 1–42.Google Scholar
2.DeGruttola, V, Seage, GR III, Mayer, KH, et al.Infectiousness of HIV between male homosexual partners. J Clin Epidemiol 1989;42:849–856.Google Scholar
3.Varghese, B, Maher, JE, Peterman, TA, Branson, BM, Steketee, RW. Reducing the risk of sexual HIV transmission: quantifying the per-act risk for HIV on the basis of choice of partner, sex act, and condom use. Sex Transm Dis 2002;29:38–43.CrossRefGoogle ScholarPubMed
4.European Study Group. Comparison of female to male and male to female transmission of HIV in 563 stable couples. BMJ 1992;304:809–813.CrossRefGoogle Scholar
5.Page-Shafer, K, Shiboski, CH, Osmond, DH, et al.Risk of HIV attributable to oral sex among men who have sex with men and in the population of men who have sex with men. AIDS 2002;16:2350–2352.Google Scholar
6.Kaplan, EH, Heimer, R. HIV incidence among New Haven needle exchange participants: updated estimates from syringe tracking and testing data. J Acquir Immune Defic Syndr Hum Retrovirol 1995;10:175–176.Google Scholar
7.Centers for Disease Control and Prevention. Case-control study of HIV seroconversion in health care workers after percutaneous exposure to HIV-infected blood: France, United Kingdom and United States, January 1988-August 1994. MMWR 1995;44:929–933.Google Scholar
8.Cardo, DM, Culver, DH, Ciesielski, CA, et al.A case-control study of HIV seroconversion in health care workers after percutaneous exposure. Centers for Disease Control and Prevention Needlestick Surveillance Group. N Engl J Med 1997;337:1485–1490.Google Scholar
9.Connor, EM, Sperling, RS, Gelber, R, et al.Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. Pediatric AIDS Clinical Trials Group Protocol 076 Study Group. N Engl J Med 1994;331:1173–1180.CrossRefGoogle Scholar
10.Otten, RA, Smith, DK, Adams, DR, et al.Efficacy of postexposure prophylaxis after intravaginal exposure of pig-tailed macaques to human-derived retrovirus (human immunodeficiency virus type 2). J Virol 2000;74:9771–9775.CrossRefGoogle ScholarPubMed
11.Tsai, CC, Emau, P, Follis, KE, et al.Effectiveness of post-inoculation R-9-(2-phosphonylmethoxypropyl) adenine treatment for prevention of persistent simian immunodeficiency virus SIVmne infection depends critically on timing of initiation and duration of treatment. J Virol 1998;72:4265–4273.CrossRefGoogle Scholar
12.Teixeira Garcia, M, Morales Figueiredo, R, Moretti, ML, et al.Postexposure prophylaxis after sexual assaults: a prospective cohort study. Sex Transm Dis 2005;32:214–219.Google Scholar
13.Smith, DK, Grohskopf, LA, Black, RJ, et al.Antiretroviral postexposure prophylaxis after sexual, injection-drug use, or other nonoccupational exposure to HIV in the United States: recommendations from the U.S. Department of Health and Human Services. MMWR Recomm Rep 2005;54(RR-2): 1–20.Google ScholarPubMed
14.New York State Department of Health AIDS Institute. HIV Prophylaxis Following Non-Occupational Exposure Including Sexual Assault. New York: New York State Department of Health; 2004. Available at: http://www.hivguidelines.org/. Accessed April 20, 2006.Google Scholar
15.Balzarmi, J, Hao, Z, Herdewijn, P, et al.Intracellular metabolism and mechanism of anti-retrovirus action of 9-(2-phosphonylmethoxyethyl) adenine, a potent anti-human immunodeficiency virus compound. Proc Natl Acad Sci 1991;88:1499–1503.CrossRefGoogle Scholar
16.Kearny, BP, Flaherty, JF, Shah, J. Tenofovir disoproxil fumarate: clinical pharmacology and pharmacokinetics. Clin Pharmacokinet 2004;43:595–612.Google Scholar
17.Schooley, RT, Ruane, P, Myers, RA, et al.Tenofovir DF in antiretroviral-experienced patients: results from a 48-week, randomized, double-blind study. AIDS 2002;16:1257–1263.CrossRefGoogle ScholarPubMed